Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents.
OBJECTIVE
To evaluate the vascular response at 9 months after zotarolimus-eluting stent (ZES; Endeavor) implantation using optical coherence tomography (OCT). These findings were compared with those after implantation of a sirolimus-eluting stent (SES; Cypher Select).


METHODS
Cross-sectional observational study with prospective OCT registry.


METHODS
Nine months after ZES or SES implantation.


METHODS
A total of 68 patients (32 ZES and 36 SES) underwent OCT at 9 months after stent implantation. The neointima hyperplasia (NIH) thickness inside each strut and percentage of NIH area at every 1 mm cross section were measured.


METHODS
The degree of neointimal coverage and the prevalence of malapposition at 9 months after ZES and SES implantation using OCT.


RESULTS
The mean (SD) NIH thickness (251.2 (110.0) mum vs 85.5 (53.3) mum, p<0.001) and percentage of NIH area (27.9 (9.1)% vs 11.2 (7.1)%, p<0.001) were significantly greater in ZES than in SES. The prevalence of uncovered strut as well as malapposed strut was significantly lower in ZES than in SES (0.3% vs 12.3%, p<0.001 and 0.08% vs 2.6%, p<0.001). Thrombus was not observed in ZES (0.0% in ZES vs 27.8% in SES, p = 0.001).


CONCLUSIONS
Neointimal coverage in ZES was almost complete and malapposition was very rare at 9-months' follow-up.
Kim
J-S
JS
Division of Cardiology, Yonsei Cardiovascular Centre, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, 120-752 Seoul, Korea.
Jang
I-K
IK
Kim
J-S
JS
Kim
T H
TH
Takano
M
M
Kume
T
T
Hur
N W
NW
Ko
Y-G
YG
Choi
D
D
Hong
M-K
MK
Jang
Y
Y
D023921:Coronary Stenosis / Q000188:drug therapy* / Q000473:pathology; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D020123:Sirolimus / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D017539:Tunica Intima / Q000473:pathology
D007166:Immunosuppressive Agents; C489443:zotarolimus; D020123:Sirolimus